On September 5, 2022 Center for Translational Research CTR reported that it is a group of complementary life science service companies providing expert services and advice within product development (Press release, Symeres, SEP 5, 2022, View Source [SID1234618992]). The services provided by Admescope Sweden/Metasafe complements well the current offerings and will contribute to a more seamless development process bringing value for our customers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Metabolites in safety testing (MIST studies) is a natural component of the early clinical development program and thereby fits very well with the services provided by the CTR-group. By this transfer, the expansion of CTR continues to build on combining key competencies and technologies with the capability to cover projects from pre-clinical to market approval.
The collaboration between the CTR-group and Admescope and Symeres will further strengthen the access to key competences and techniques in pre-clinical development.
The activities will continue without interruption and with the same staff, in the same facilities, using the same instrumentation. Johanna Haglund, Business Development Scientist and Head of Safety Metabolism, will lead the team.
Karin Meyer, CEO at CTR says: "Through the transfer of Admescope Sweden/Metasafe to our group we will be able to offer a more integrated approach and develop the services for our customers using the talented staff and facilities in the human metabolite profiling and characterisation area. We look forward to the collaboration with Admescope and Symeres, aiming for a more complete solution for several projects."
Outi Kontkanen, CEO Admescope says: "Admescope, as part of Symeres, continues to focus on delivering tailored solutions in non-clinical ADME support and toxicology, with strategic investments to further expand our services in these areas globally. We look forward to continued collaborations with the CTR group and are pleased that our talented MIST-team has a new home where it fits to the clinical drug development landscape."
Symeres CEO Eelco Ebbers comments: "With this transfer we will have a very logical consolidation of our ADME services at two sites, namely Nijmegen in the Netherlands and Oulu in Finland which allows us to focus our development investments. Symeres looks forward to further collaboration with CTR which will strengthen our access to key competences and techniques in pre-clinical development."